Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor
View HTML
Toggle Summary "THINK FUNGUS" - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
The first Fungal Disease Awareness Week is designed to increase awareness about fungal diseases, which can cause severe illness but frequently go undiagnosed
View HTML
Toggle Summary SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue Positive efficacy data reported from proof-of-concept Phase 2 VVC study JERSEY CITY, N.J., Aug. 14, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative
View HTML
Toggle Summary SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
Dosing Initiated in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Recent Data Publications Showcase Broad and Potent Activity of SCY-078 Against Multiple Fungal Species Including Candida auris JERSEY CITY, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS to Present at the Canaccord Genuity Growth Conference
JERSEY CITY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the Canaccord Genuity Growth
View HTML
Toggle Summary SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
Study initiation marks important milestone following promising clinical results in previous Phase 2 study Additional pre-clinical results for VVC to be presented at upcoming 2017 IDSOG Annual Meeting JERSEY CITY, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary New Study Further Demonstrates In Vitro Activity of SCYNEXIS' Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
Supports SCY-078's Activity Against Emerging Echinocandin-Resistant Candida Species
View HTML
Toggle Summary SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer,
View HTML
Toggle Summary Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078
Potent and broad activity of SCY-078 shown against more than 300 clinical Candida isolates    Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile   JERSEY CITY, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections
JERSEY CITY, N.J., May 24, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced eight poster presentations at ASM Microbe 2017 , June 1 through 5 in
View HTML